Business Wire Feed

C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease

March 19th, 2026|

ST. LOUIS--(BUSINESS WIRE)--#ADPD2026--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset (Evoke/Evoke+), reflecting ongoing more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.